In 2017, Pazhang et al. [13] have demonstrated survivin down‐regulation in HL-60 cancer cells using embelin and celastrol, two anti-tumor agents, led to considerable response improvement to chemotherapeutic agents and diminished NF-κB activity, because of the crosstalk existence between X-linked IAP and NF-κB pathway. This evidence concerns the gene BIRC5 and cancer.